A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma
Theranostics · 2026
DOI: 10.7150/thno.127558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Hyung Shik Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Glioblastoma, Cancer Vaccines, Antigen Presentation, RNA, Messenger. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114, USA.
- Graduate School for Biomedical Science & Engineering, Hanyang University, 04763, Seoul, Korea.
- Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Kim, H. S., Oh, J., Jeon, J., Fei, F., Parvanian, S., Kohler, R., Garris, C., & Weissleder, R. (2026). A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma. Theranostics. https://doi.org/10.7150/thno.127558
Vancouver
Kim HS, Oh J, Jeon J, Fei F, Parvanian S, Kohler R, et al. A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma. Theranostics. 2026. doi:10.7150/thno.127558
BibTeX
@article{Kim2026,
author = {Kim, Hyung Shik and Oh, Juhyun and Jeon, Jueun and Fei, Fan and Parvanian, Sepideh and Kohler, Rainer and Garris, Christopher and Weissleder, Ralph},
title = {A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.127558}
}
EUVIMED